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LEARNING OBJECTIVES
After completing this course, the reader will be able to:
1. Explain the difference in survival prediction between response criteria (WHO) when used as a two-level variable
(CR/PR vs. other) and as a three-level variable (CR/PR vs. SD vs. PD).
2. Describe the limited benefit of using actual tumor measurements over traditional criteria (as a three-level variable)
in predicting survival in colorectal cancer.
This article is available for continuing medical education credit at CME.TheOncologist.com.CME
ABSTRACT
Purpose. We explored the prognostic value of actual tu-
mor measurements (TM) versus World Health Organi-
zation (WHO) criteria as three-level (responder, stable,
and progression) and two-level (responder and non-
responder) variables at 12 and 24 weeks as predictors of
survival in Intergroup Trial N9741, a phase III trial in
metastatic colorectal cancer (CRC).
Methods. All patients with measurable disease (N 
1,188) were included. The percentage changes in TM
from baseline to 12 and 24 weeks were calculated. The
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prognostic values of TM versus WHO criteria (as three-
and two-level variables) at 12 and 24 weeks were com-
pared, using Cox models for overall survival (OS) in a
landmark analysis, adjusting for baseline tumor size,
performance status, and treatment arm.
Results. Tumor status at 12 weeks by WHO criteria
(three or two levels) or actual TM were all strongly as-
sociated with OS. Actual TM provided no meaningful
additional benefit compared with the three-level WHO
criteria. Tumor status at 24 weeks was also strongly as-
sociated with survival, but added no additional prog-
nostic value compared with the 12-week assessment. At
12 weeks, actual TM improved prognostic characteriza-
tion of patients with WHO status of response, but pro-
vided no additional value in patients with stable disease
or progression.
Conclusions. In N9741, the use of actual TM, or follow-
ing tumor status beyond 12 weeks, did not improve sur-
vival prediction compared with a single three-level
response assessment at 12 weeks, suggesting that 12-week
tumor status could be an appropriate phase II trial end-
point in metastatic CRC. The Oncologist 2011;16:859–867
INTRODUCTION
Endpoints used in colorectal cancer (CRC) trials have come
under intense scrutiny as we continue to determine clini-
cally meaningful outcomes [1–8]. The controversy pertains
not only to phase III trials, but also to phase II trials, which
are critical in providing insight into which drugs should ad-
vance to phase III testing [3, 9]. Phase II trials are employed
to identify promising therapeutics, and to eliminate as effi-
ciently as possible those agents doomed to ultimately fail.
There are numerous phase II studies which showed prom-
ising activity for single agents and combinations of agents
that when tested in larger and costly phase III studies led to
negative results [10, 11].
The traditional binary endpoint in CRC of response rate
(RR) as determined by established criteria (Response Eval-
uation Criteria in Solid Tumors [RECIST] or World Health
Organization [WHO]) [12, 13] has helped to identify prom-
ising cytoreductive agents to promote to future studies.
However, RR alone has been a poor predictor of eventual
success in phase III trials [11, 14]. Using the two-level ap-
proach of RR (responder, non-responder) does not include
stable disease (SD) in response. We know, nonetheless, that
patients treated with traditional cytoreductive chemother-
apy can still experience a clinical benefit without a signifi-
cant change in tumor size [8]. With many new biologic
agents now being tested that may offer significant clinical
benefit with a cytostatic rather than cytoreductive mecha-
nism of action [3, 8], the use of RR as the primary endpoint
in early phase II trials may overlook the potential benefit of
such agents.
Though other endpoints have been proposed, progres-
sion-free survival (PFS) currently remains the most widely
accepted alternative endpoint to overall survival in phase III
trials for CRC. The PFS endpoint takes into account not
only those patients with tumor shrinkage but also those with
stable disease who may still garner a meaningful clinical
benefit from cytostatic drugs [1, 15, 16]. A similar endpoint
for phase II trials in CRC that includes the benefit of stable
disease is desirable. Simply moving from the binary end-
point of RR to the time-to-event variables of PFS or time to
progression (TTP) in phase II trials includes in the estimate
of benefit those agents capable of producing stable disease.
However, this also adds significant time and expense to an
early stage trial. Because median PFS times with current
combination therapies in first-line CRC are now approxi-
mately 8–10 months, the identification of other, earlier end-
points for phase II trials is desirable. The use of PFS or TTP
at a specific time point is one appealing strategy for phase II
trials and has the potential to provide clinically useful in-
formation in a cost-efficient and timely manner. Such a
model has been studied in glioblastoma multiforme (GBM)
[17], resulting in validation of PFS at 6 months as the pri-
mary endpoint in many phase II trials in that setting [18–
21]. An 8-week assessment of tumor status has been studied
in lung cancer and found to be predictive of survival [22].
Mathematical models incorporating change in tumor size at
7 weeks have been developed in CRC to help predict sur-
vival in future studies [23]. To our knowledge, no study has
yet evaluated the survival prediction of tumor status at spe-
cific time points in CRC as a possible endpoint for future
studies.
It has been suggested that the use of actual tumor size
(often expressed via waterfall plots) may provide an addi-
tional valuable measure of antitumor activity [24]. The use
of a continuous endpoint of change in actual tumor size has
also been suggested as an alternative to the traditionally es-
tablished criteria, such as RECIST or WHO, in predicting
the true benefit of a drug [25]. The thought is that a patient
with tumor shrinkage of 15% will likely do better than a pa-
tient with tumor growth of 15%, yet they are both listed as
“stable disease” under the established RECIST criteria
[12]. In many studies, however, continuous endpoints of ac-
tual change in tumor size report the “best” response for each
patient throughout the study rather than at an equal and spe-
cific time point, which can make interpretation of the re-
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sults to an individual patient quite difficult, and ultimately
may lessen the value of the information.
In this study, we explored the prognostic value of tumor
measurements at 12 weeks and 24 weeks as predictors of sur-
vival in Intergroup Trial N9741, which compared irinotecan
and bolus fluorouracil plus leucovorin (IFL), oxaliplatin and
infused fluorouracil plus leucovorin (FOLFOX), and irinote-
can and oxaliplatin (IROX) as first-line therapy in advanced
CRC [26]. Our aims are (a) to determine whether an early cat-
egorical endpoint of tumor assessment is capable of predicting
survival in colorectal cancer and (b) to compare the prognostic
value of actual tumor measurements (TM) versus the tradi-
tional WHO criteria (both as a three-level variable that incor-
porates SD and as a two-level variable that does not include
SD in response) at these time points.
PATIENTS AND METHODS
Patients (N  1,188) from the North Central Cancer Treat-
ment Group (NCCTG) N9741 trial comparing frontline
chemotherapy in metastatic colon cancer with measurable
disease were included in the analysis. Baseline patient char-
acteristics are given in Table 1. Actual tumor measurements
were obtained and the percentage changes in TM for each
patient from baseline to 12 weeks and 24 weeks were cal-
culated. If a 12-week measurement was not available, tu-
mor measurements obtained during the closest assessment
made during weeks 6–18 were used. For the 12-week land-
mark analysis, 90 of 1,188 patients did not have a radio-
graphic assessment within the 6- to 18-week time frame.
For these 90 patients, we assigned a 50% increase in TM if
they had a clinical status of “progression” during the time










12 wks: mean (SD)
11.9 (2.3) 11.6 (2.6) 11.7 (2.3) 11.7 (2.5)
Assessment time 24 wks:
mean (SD)
23.8 (1.8) 23.6 (2.2) 23.9 (2.1) 23.8 (2.1)
Follow-up months in patients










Tumor status at 12 wks
Responder (CR/PR) 114 (34%) 237 (43%) 98 (33%) 449 (38%)
Stable 146 (43%) 251 (45%) 132 (45%) 529 (45%)
Progression 78 (23%) 66 (12%) 66 (22%) 210 (18%)
Tumor status at 24 wks
Responder 103 (30%) 232 (42%) 90 (30%) 425 (30%)
Stable 87 (26%) 165 (30%) 80 (27%) 332 (27%)
Progression 148 (44%) 157 (28%) 126 (43%) 431 (43%)
Overall confirmed status
Responder 121 (36%) 270 (49%) 114 (39%) 505 (43%)
Age: mean (SD) 59.5 (11.1) 60.5 (11.5) 59.8 (11.8) 60 (11.5)
Male 225 (67%) 332 (60%) 180 (61%) 737 (62%)
Prior adjuvant chemotherapy 51 (15%) 87 (16%) 39 (13%) 177 (15%)
PS
0–1 327 (97%) 530 (96%) 280 (95%) 1137 (96%)
2 11 (3%) 24 (4%) 16 (5%) 51 (4%)
Race
White 290 (86%) 469 (85%) 255 (86%) 1014 (85%)
Black 35 (10%) 38 (7%) 24 (8%) 97 (8%)
Hispanic 9 (3%) 24 (4%) 10 (4%) 43 (4%)
Other 4 (1%) 23 (4%) 7 (2%) 34 (3%)
Abbreviations: CI, confidence interval; CR, complete response; FOLFOX, oxaliplatin and infused fluorouracil plus
leucovorin; IFL, irinotecan and bolus fluorouracil plus leucovorin; IROX, irinotecan and oxaliplatin; PR, partial response;
PS, performance status; SD, standard deviation.
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frame (N  28) and 0% change if they did not have progres-
sion (N  62). Similarly, for the 24-week assessment, if no
24-week tumor measurement was available, we used mea-
surements from the closest assessment made during weeks
18–30 to calculate the percentage change in TM. For the
24-week landmark analysis, 378 of 1,116 patients did not
have a radiographic assessment within the 18- to 30-week
time frame. For these 378 patients, we again assigned a 50%
increase in TM if they had a clinical status of “progression”
during the time frame (N  226) and 0% change if they did
not have progression (N  152). For modeling, the trans-
formation log(1.01  % change) and log(baseline measure-
ment/absolute change) was used to provide normality.
WHO criteria assess the sum of the products of index le-
sions, requiring a 50% reduction for partial response (PR),
complete disappearance for complete response (CR), and a
25% increase for progressive disease (PD), with all other mea-
surements representing stable disease (SD) [13]. WHO criteria
require confirmation of response after 4 weeks for patients
with PR or CR. In this study, WHO disease status at 12 and 24
weeks was considered as both a two-level (response [CR/PR]
versus no response [SD, PD]) and a three-level (response, sta-
ble, and progression) variable. The WHO status reported at the
time of the tumor measurement was used with the time frames
described above.
Tumor measurements in N9741 were obtained by the
treating institution and measures were taken to review
data quality beyond the normal study data validation. In
the original study, 10% of cases were selected for quality
assurance with review of clinical reports and data collec-
tion by the primary investigator with no concerns recog-
nized. The FDA also performed audits on selected sites
(as N9741 was the registration study for the first-line in-
dication for FOLFOX) with no concerns in data collec-
tion identified.
The prognostic value of actual change in tumor size,
versus WHO disease status (both as a two-level and a three-
level variable), were compared at 12 and 24 weeks using
Cox models for OS after 12 weeks and after 24 weeks, re-
spectively, in a landmark analysis, adjusting for baseline tu-
mor size, performance status, and treatment arm. The
prognostic value for each model was assessed using the
concordance index C. The concordance index is similar to a
correlation coefficient from a simple two-way association,
or R2 from a linear regression. The concordance index is a
useful supplement to a p value in a Cox regression. p values
may be statistically significant but the result not clinically
meaningful. The concordance index provides information
regarding the strength of the relationship between the vari-
ables and outcomes, where 0.5 means there is no associa-
tion and 1.0 means that there is a perfect association or
prediction ability. The added value of confirmation of re-
sponse was assessed using a landmark analysis starting at
24 weeks after randomization, comparing 12-week disease
status with disease status at 24 weeks, where to be declared
a responder at 24 weeks, the response must have been main-
tained for at least 4 weeks.
RESULTS
Multivariate analyses for overall survival with the 12-week
landmark time point are reported in Table 2. WHO status at
12 weeks was strongly associated with survival when used
as either a three-level (p  .01) or two-level variable (p 
.01). Actual TM were also strongly associated with OS at 12
weeks (p  .01), but provided no meaningful additional
Table 2. Multivariate analysis for overall survival (12-
week landmark, N  1,188)




Stablea 1.09 (0.93, 1.27) .28
Progressiona 2.89 (2.48, 3.37) .01
PSc 1.48 (1.07, 2.07) .02
Arm F (FOLFOX)b 0.69 (0.60, 0.80) .01
Arm G (IROX)b 0.83 (0.70, 0.98) .03
Log(baseline measure) 1.27 (1.21, 1.34) .01
12-week tumor status (two-
level variable); C  0.65
Non-respondera 2.81 (2.40, 3.29) .01
PSc 1.59 (1.19, 2.13) .01
Arm F (FOLFOX)b 0.68 (0.59, 0.79) .01
Arm G (IROX)b 0.85 (0.73, 1.00) .05
Log(baseline measure) 1.27 (1.20, 1.34) .01
12-week actual TM percentage
change; C  0.64
Log(% change at 12 wks) 1.49(1.37, 1.63) .01
PSc 1.68 (1.26, 2.25) .01
Arm F (FOLFOX)b 0.69 (0.59, 0.79) .01
Arm G (IROX)b 0.88 (0.75, 1.03) .11
Log(baseline measure) 1.24 (1.18, 1.31) .01
aResponse of CR/PR is the reference group for confirmed
response comparisons.
bArm A (IFL) is reference group for treatment
comparisons.
cReference is 0–1.
Abbreviations: CI, confidence interval; CR, complete
response; FOLFOX, oxaliplatin and infused fluorouracil
plus leucovorin; HR, hazard ratio; IFL, irinotecan and
bolus fluorouracil plus leucovorin; IROX, irinotecan and
oxaliplatin; PR, partial response; PS, performance status;
TM, tumor measurement.
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predictive value (C  0.64) compared to the WHO three-
level assessment (C  0.66).
A confirmatory analysis with the 24-week landmark
was performed with similar results (Table 3). WHO status
as a two-level variable and actual TM remained strongly as-
sociated with survival when analyzed at 24 weeks; how-
ever, the 24-week status provided no meaningful additional
predictive value (C  0.68) compared to 12 weeks (C 
0.66). The three-level WHO status at 24 weeks provided no
added value compared to tumor status as a two-level vari-
able at 24 weeks, as the difference in survival for stable pa-
tients versus responding patients disappeared (p  .28).
Restricting the analysis to consider only confirmed re-
sponses in the 24-week landmark analysis did not seem to
add value (p  .01, C  0.69).
Kaplan-Meier estimates of OS based on 12- and 24-
week tumor status are found in Figure 1. There is clear sep-
aration (p  .01) in the survival curves when a three-level
variable is used for the WHO criteria at 12 weeks, but there
is no difference in survival between responding and stable
patients at 24 weeks.
To further explore any potential benefit of actual TM
over WHO status as a three-level variable, a subset analysis
was performed within each of the 3 categorizations of re-
sponse, where overall survival was modeled by percent
change of tumor measurements alone (Table 4). Of the
three categories, tumor measurements were associated with
survival within CR/PR patients (p  .01), but not within pa-
tients with SD (p  .87) or progression (p  .81) (Figure 2).
Of note, within CR/PR patients the survival curves sepa-
rated only after 15 months.
DISCUSSION
The search for promising endpoints for phase II trials in on-
cology is highly relevant and is the subject of active inves-
tigation. In this report, we have provided data from a large
randomized phase III trial in CRC that provides hypothesis
generating results for the development of novel endpoints
for randomized phase II studies. First, in our data set, tumor
status, as a three-level variable at 12 weeks, that incorpo-
rates SD, was an important predictor of survival and pro-
vided identification of additional clinical benefit compared
to RR alone. There are distinct separations in the survival
curves when comparing patients whose 12-week status was
CR/PR versus SD versus PD. This indicates that using RR
alone (CR/PR) as an endpoint in phase II trials will miss po-
tentially clinically beneficial agents that may offer disease
control. We know from previous studies that patients in
N9741 without a tumor response still received a clinical
benefit from these traditionally cytoreductive therapies [8],
but this analysis now shows further separation among “non-
responders” by separating survival curves for those patients
with stable disease and those with progressive disease. This
finding, demonstrated in a large study using response in-
ducing agents, is likely to be even more relevant in the era
of cytostatic biologic agents used alone or in combination
with traditional chemotherapy.
Second, actual tumor measurements provided little ad-
ditional benefit over WHO status (considered as a three-
level variable; CR/PR, SD, PD) at 12 weeks to predict
subsequent patient survival. This is another critical finding
that may provide guidance in designing future phase II tri-
als. In evaluating the survival curves separately for patients
with 12-week status of CR/PR, SD, and PD, actual tumor
measurements provided additional predictive ability for
only one group—those patients achieving a response. This
Table 3. Multivariate analysis for overall survival
(24-week landmark, N  1,116)
Variable HR (95% CI) p
Tumor status (three-level
variable); C  0.68
Stablea 1.09 (0.93, 1.27) .28
Progressiona 2.89 (2.48, 3.37) .01
PSc 1.48 (1.07, 2.07) .02
Arm F (FOLFOX)b 0.69 (0.60, 0.80) .01
Arm G (IROX)b 0.83 (0.70, 0.98) .03
Log(baseline measure) 1.25 (1.19, 1.33) .01
Tumor status (two-level
variable); C  0.69
Non-respondera 2.78 (2.42, 3.18) .01
PSc 1.51 (1.08, 2.10) .02
Arm F (FOLFOX)b 0.70 (0.61, 0.82) .01
Arm G (IROX)b 0.83 (0.70, 0.99) .04
Log(baseline measure) 1.23 (1.17, 1.30) .01
Actual TM percentage change;
C  0.65
Log(% change at 24 wks) 1.36 (1.27, 1.45) .01
PSc 1.42 (1.02, 1.97) .04
Arm F (FOLFOX)b 0.71 (0.61, 0.82) .01
Arm G (IROX)b 0.88 (0.75, 1.05) .15
Log(baseline measure) 1.23 (1.17, 1.30) .01
aResponse of CR/PR is the reference group for 24-week
response comparisons.
bArm A (IFL) is reference group for treatment
comparisons.
cReference is 0–1.
Abbreviations: CI, confidence interval; CR, complete
response; FOLFOX, oxaliplatin and infused fluorouracil
plus leucovorin; HR, hazard ratio; IFL, irinotecan and
bolus fluorouracil plus leucovorin; IROX, irinotecan and
oxaliplatin; PR, partial response; PS, performance status;
TM, tumor measurement.
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indicates a potential difference in survival benefit based on
the extent of the response, but the usefulness of this finding
may be of only a modest benefit in early trials. Especially in
phase II trials, the key determination is whether there is
truly a clinical benefit of a therapy to promote further con-
firmatory studies, not to further clarify the range of benefit
among those patients responding. Further, the survival ad-
vantage for patients with greater response emerged only af-
ter extended follow-up. Thus, the use of traditional
established disease status criteria, when expanded to a
three-level factor as opposed to the traditional responder/
non-responder classification in phase II trials, appears to be
adequate. Whether there is a role for actual tumor measure-
ments in larger phase III trials as well as whether the prog-
nostic value added to those patients responding will be of
benefit for clinicians in practice remains to be determined.
Using actual tumor measurements as a continuous end-
point in phase II trials has been suggested to offer the ben-
efit of smaller sample sizes, but the value of these
measurements in predicting survival had not been validated
[25]. The assumption that a patient with tumor growth of
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Figure 1. Kaplan-Meier estimates of overall survival based on 12- and 24-week tumor status. (A): Overall survival based on
12-wk tumor status (World Health Organization criteria, three-variable model). Median survival: responder  20.7 mos; stable 
16.2 mos; progression  7.2 mos. (B): Overall survival based on 24-week tumor status (World Health Organization criteria, three-
variable model). Median survival: response  18.8 mos; stable  17.0 mos; progression  6.0 mos.
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was not demonstrated in our analyses and calls into ques-
tion the added value of actual tumor measurements over tra-
ditional categorical disease assessment criteria at least in
early phase studies. The suggestion to treat actual tumor
measurements as longitudinal data over time [25] may ulti-
mately require a longer study duration and likely negate the
benefit of the reduced sample size in regards to trial feasi-
bility.
Third, neither continuous tumor measurements at 24
weeks, nor WHO status at 24 weeks, nor confirmed re-
sponse within the first 24 weeks added prognostic value
compared to tumor status at 12 weeks in patients with ad-
vanced CRC. The traditional WHO and RECIST criteria re-
quire confirmation of response at four weeks, but the data
here suggest that may not be required. The updated RE-
CIST 1.1 criteria still require confirmation of response if
the trial’s primary endpoint is tumor response rate, but no
longer require confirmation in randomized studies [27].
The findings from this study suggest that as a primary end-
point, a 12-week assessment in patients with CRC alone
may provide an adequate measure of the benefit of therapy,
thus improving feasibility and controlling costs otherwise
incurred if using other time-dependent variables.
Using a fixed-time disease status variable has also been
studied in other tumors with favorable results [22]. Ballman
et al. compared the relationship between 6-month PFS and
12-month overall survival in phase II trials in patients with
glioblastoma multiforme and determined that PFS at 6
months was a reasonable endpoint for phase II trials in pa-
tients with GBM [17]. This assessment has led to a shift in
phase II trial design in neurooncology and many GBM
phase II trials now use 6-month PFS rate as the primary end-
point. Lara et al. evaluated disease control rate (CR/PR/SD)
at 8 weeks in patients with advanced non–small cell lung
cancer and found that disease control rate at 8 weeks not
only provided an early assessment of subsequent outcomes,
but was also a more powerful predictor of survival than the
RR alone [22].
Our study also provides potential benefit to clinicians in
counseling patients regarding their clinical response to ther-
apy at 12 weeks. Early tumor evaluation in predicting clin-
ical outcomes has been evaluated in other tumor sites [22,
28–30] as well as colorectal cancer [31–34]. It is notable,


















































Figure 2. Added benefit of percentage of change in tumor
measurement at 12 wks by tumor status. (A): Responsive dis-
ease (complete response/partial response). Median time to sur-
vival: 100%– 65% decrease  22.8 mos; 65%–50%
decrease  18.5 mos. (B): Stable disease. Median time to sur-
vival: 50%–25% decrease  17.6 mos; 0 –25% decrease 
14.6 mos; 0–25% increase  15.0 mos. (C): Progressive dis-
ease. Median time to survival: 50% increase  6.8 mos;
25%–50% increase  7.3 mos.
Table 4. Univariate analysis of percentage change within
12-week tumor status categories
Tumor
status Variable HR (95% CI) p
CR/PR Log(% change) 1.29 (1.12, 1.48) .01
Stable Log(% change) 1.03 (0.72, 1.49) .87
Progression Log(% change) 1.03 (0.82, 1.30) .81
a12-week landmark analysis.
Abbreviations: CI, confidence interval; CR, complete
response; HR, hazard ratio; PR, partial response.
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are now a standard part of therapy in advanced CRC. Be-
cause the therapeutic agents used (i.e., biologic or other cy-
tostatic agents) may also influence the overall prognostic
value of tumor status in CRC [34], caution must be exer-
cised by clinicians before using this information in counsel-
ing patients until further analysis is available.
The inclusion of stable disease at 12 weeks as an end-
point in phase II trials in CRC heightens the importance of
randomization to a concurrent control arm to help distin-
guish natural tumor biology and supportive care benefits
from potentially disease controlling agents [3, 14]. Though
randomization will increase the sample size required, using
the endpoint of a 12-week tumor assessment in CRC will
limit the duration of the study, ensuring that these early
studies will be not only feasible, but also more fruitful.
There are limitations to our study that should be ac-
knowledged. These findings are from a single, large clinical
trial, with response-inducing agents. Most patients (75%)
had 3 assessed lesions; thus, the sum of tumor measure-
ments may not reflect the entire tumor burden. Greater than
50% of patients received second-line and later-line thera-
pies, possibly reducing the relationship between first-line
tumor shrinkage and eventual survival. Only a small num-
ber of patients with CR (N  23) were included. Though
central radiologic review was not required, quality assur-
ance procedures were followed, allowing this study to yield
results from “real world” data. Importantly, the findings
from this study are based on agents that frequently induce
tumor shrinkage and therefore, analysis should be repeated
from large clinical trials using cytostatic agents. Results of
this study are potentially useful in phase II trials for colon
cancer, but there should be caution in extrapolating results
to other tumor types as therapeutic agents and tumor biol-
ogy will differ. None of the measures assessed here pro-
vided highly accurate prediction, as assessed by the
concordance index, indicating the continued need to de-
velop new early clinical trial endpoints.
CONCLUSION
In this large phase III randomized trial, tumor status as a
three-level variable (CR/PR, SD, PD) at 12 weeks after ran-
domization predicted subsequent overall survival and may
be an appropriate and feasible endpoint for further consid-
eration in future phase II clinical trials for CRC. Actual tu-
mor measurements versus a three-level WHO criteria at 12
weeks offered only a mild improvement in survival predic-
tion, limited only to those patients with a tumor response.
Following tumor status for 12 weeks, with either actual
tumor measurements or by WHO criteria, and the require-
ment of confirming a response did not improve survival
prediction compared to a single assessment at 12 weeks.
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